XPOVIO® Gains Approval in Hong Kong for Multiple Myeloma Treatments

On December 3, 2025, the Hong Kong Department of Health approved XPOVIO® (selinexor) for two additional indications, expanding its use in treating multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). This approval allows for XPOVIO® to be utilized as a monotherapy for adult patients with relapsed or refractory DLBCL and in combination with bortezomib and dexamethasone for adults with MM who have undergone at least one prior therapy.

The latest approvals build upon the previous endorsement of XPOVIO® as part of a regimen with dexamethasone for adult patients suffering from relapsed/refractory MM. The recent updates are expected to significantly broaden access to this treatment, potentially offering substantial survival benefits to a wider array of patients in Hong Kong.

Innovative Treatment Options for Patients

As the first approved selective XPO1 inhibitor in Hong Kong, XPOVIO® introduces a novel mechanism of action that could improve outcomes for patients with challenging hematologic malignancies. The approval for its use in combination with bortezomib and dexamethasone (referred to as XVd) provides a new option for those who have not responded to standard therapies.

Antengene Corporation Limited, the developer of XPOVIO®, aims to address significant unmet medical needs within the oncology sector. The company has already secured approvals for the drug in ten countries across the Asia-Pacific region and has seen XPOVIO® included in national insurance schemes in five markets, including Mainland China, Taiwan, Australia, Singapore, and South Korea.

Antengene’s Commitment to Innovation

Antengene Corporation, listed on the Hong Kong Stock Exchange (SEHK: 6996.HK), focuses on developing first-in-class and best-in-class therapeutics for various diseases, including autoimmune disorders and hematological cancers. The company’s pipeline includes several promising candidates, such as ATG-022, ATG-037, and ATG-101, which target a range of conditions.

The firm has achieved significant milestones, with 32 investigational new drug approvals in the U.S. and Asia. As the company continues to expand its reach, it anticipates further public insurance coverage for XPOVIO® across more markets in the Asia-Pacific region. This expansion is expected to enhance treatment accessibility for patients facing severe health challenges associated with multiple myeloma and diffuse large B-cell lymphoma.

Antengene remains committed to its mission of improving patient outcomes through innovative therapies. With the recent approvals in Hong Kong, the company is poised to make a meaningful impact on the lives of patients battling these complex diseases.